⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
businesswire.com
GMAB
ABBV
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
globenewswire.com
GMAB
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
globenewswire.com
GMAB
Genmab Announces TEPKINLY ® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
businesswire.com
GMAB
Genmab appoints Matt Kiely as General Manager for the United Kingdom
globenewswire.com
GMAB
MHRA Grants Marketing Authorisation to TIVDAK® ▼ (tisotumab vedotin) for the Treatment of Recurrent or Metastatic Cervical Cancer with Disease Progression On or After Systemic Therapy
globenewswire.com
GMAB